| Identification | Back Directory | [Name]
LOC-14 | [CAS]
877963-94-5 | [Synonyms]
OC14
LOC-14
LOC 14;LOC14
2-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]methyl]-1,2-benzisothiazol-3(2H)-one
2-((4-(cyclopropanecarbonyl)piperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one
1,2-Benzisothiazol-3(2H)-one, 2-[[4-(cyclopropylcarbonyl)-1-piperazinyl]methyl]-
2-[(4-cyclopropanecarbonylpiperazin-1-yl)methyl]-2,3-dihydro-1,2-benzothiazol-3-one | [Molecular Formula]
C16H19N3O2S | [MDL Number]
MFCD07849042 | [MOL File]
877963-94-5.mol | [Molecular Weight]
317.41 |
| Chemical Properties | Back Directory | [Boiling point ]
528.5±60.0 °C(Predicted) | [density ]
1.390±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:1): 0.5mg/mL; DMSO: 3mg/mL; Ethanol: 3mg/mL; Ethanol:PBS (pH 7.2) (1:6): 0.14mg/mL | [form ]
A crystalline solid | [pka]
6.16±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
LOC14 acts as a high affinity disulfide isomerase (PDI) modulator. Neuroprotective agent. | [in vivo]
LOC14 (orally administered by gavage; 20 mg/kg; once daily; 12-28 weeks) significantly improves motor function, attenuated brain atrophy and extended survival in the N171–82Q HD mice[2]. | Animal Model: | Male N171–82Q HD mice[2] | | Dosage: | 20 mg/kg | | Administration: | Orally administered by gavage; 20 mg/kg; once daily; 12-28 weeks | | Result: | Improved motor function in HD mice. |
| [storage]
4°C, protect from light ,unstable in solution, ready to use. |
|
|